Is Bupropion an SSRI? The Quick Answer Plus the Clinical Differences That Actually Matter

Direct answer (40-60 words)

No. Bupropion is not an SSRI. It's an NDRI, a norepinephrine-dopamine reuptake inhibitor. SSRIs increase serotonin. Bupropion increases norepinephrine and dopamine instead. The class difference explains why bupropion has fewer sexual side effects, less weight gain, and a more activating profile than typical SSRIs like sertraline or escitalopram.

Table of contents

1. The 30-second answer
2. What bupropion actually is (and the brand names you'll see)
3. What an SSRI actually is (and the common ones)
4. How the mechanisms differ at the synapse
5. The practical differences: side effects head-to-head
6. Weight: the part patients ask about most
7. Sexual side effects: the part patients ask about second-most
8. When bupropion is preferred, when an SSRI is preferred
9. Bupropion for smoking cessation and weight loss
10. The Contrave question
11. Safety considerations and contraindications
12. FAQ
13. Footer disclaimers

What bupropion actually is (and the brand names you'll see)

Bupropion is a generic medication classified as a norepinephrine-dopamine reuptake inhibitor, or NDRI. It was first approved by the FDA in 1985 for major depressive disorder. Since then, it's been approved for additional uses and sold under several brand names depending on the formulation and indication:

• Wellbutrin (immediate release, sustained release, extended release) for depression
• Wellbutrin XL (extended release) for depression and seasonal affective disorder
• Zyban for smoking cessation
• Aplenzin (a hydrobromide salt formulation) for depression
• Contrave (combined with naltrexone) for chronic weight management
• Auvelity (combined with dextromethorphan) for major depressive disorder

All of these contain bupropion as the active drug. The differences are in release profile, the second molecule (in combination products), and the indication on the FDA label.

Bupropion sits in its own class. There's no other NDRI antidepressant on the U.S. market with widespread use. That uniqueness is partly why it gets prescribed when other antidepressants haven't worked or have caused intolerable side effects.

What an SSRI actually is (and the common ones)

SSRI stands for selective serotonin reuptake inhibitor. SSRIs increase serotonin levels in the synaptic cleft by blocking the serotonin transporter, which would normally pull serotonin back into the presynaptic neuron after release.

The major SSRIs prescribed in the United States:

• Sertraline (Zoloft)
• Fluoxetine (Prozac, Sarafem)
• Escitalopram (Lexapro)
• Citalopram (Celexa)
• Paroxetine (Paxil, Pexeva)
• Fluvoxamine (Luvox)
• Vilazodone (Viibryd, technically an SSRI plus partial 5-HT1A agonist)

SSRIs are the first-line pharmacologic treatment for major depression and most anxiety disorders in adults. Bupropion is not in this group, despite both classes being used as antidepressants.

A related class is the SNRI (serotonin-norepinephrine reuptake inhibitor): venlafaxine (Effexor), duloxetine (Cymbalta), desvenlafaxine (Pristiq), levomilnacipran (Fetzima). SNRIs hit serotonin too, so they share the side-effect profile of SSRIs to a meaningful degree.

Bupropion does not increase serotonin. That single fact explains most of the practical differences between bupropion and the SSRI/SNRI families.

How the mechanisms differ at the synapse

Stripping out the jargon, the brain communicates between neurons by releasing neurotransmitters into the synaptic cleft (the gap between two neurons). After release, the neurotransmitter is either broken down by enzymes or pulled back into the releasing neuron by transporter proteins. Reuptake inhibitors block those transporter proteins, leaving more neurotransmitter floating in the cleft to act on receptors.

SSRIs block the serotonin transporter (SERT). Result: more serotonin in the cleft.

SNRIs block both SERT and the norepinephrine transporter (NET). Result: more serotonin and norepinephrine.

Bupropion blocks the norepinephrine transporter (NET) and the dopamine transporter (DAT). Result: more norepinephrine and dopamine.

Bupropion has minimal direct effect on serotonin pathways. It does have some additional activity at nicotinic acetylcholine receptors, which is part of why it works for smoking cessation.

The neurotransmitter mix matters because each chemical influences different functions:

• Serotonin is involved in mood regulation, appetite, sleep, sexual function, and gut motility.
• Norepinephrine is involved in alertness, attention, heart rate, and stress response.
• Dopamine is involved in motivation, focus, reward, and motor control.

Push serotonin up (SSRIs) and you tend to get the upsides of mood stabilization plus the downsides of sexual dysfunction, weight changes, and GI symptoms. Push dopamine and norepinephrine up (bupropion) and you tend to get the upsides of energy and focus plus the downsides of insomnia and elevated heart rate.

The practical differences: side effects head-to-head

This is the table most patients want to see when they're choosing between an SSRI and bupropion.

Side effect	SSRIs (typical)	Bupropion
Sexual dysfunction	30-70% (varies by drug)	5-10%
Weight gain	10-25% gain meaningful weight	Often weight neutral or modest loss
Nausea / GI issues	15-25%	3-7%
Sedation / fatigue	Common (especially paroxetine)	Rare (often activating)
Insomnia	Sometimes	Common, especially at start
Anxiety / restlessness	Sometimes early	Common, especially early
Headache	15-20%	25-30%
Dry mouth	Mild	Common (15-20%)
Sweating	10-15%	5-8%
Seizure risk	Very low	Higher (0.1-0.4% at therapeutic doses)
Discontinuation syndrome	Common, especially paroxetine	Rare
Suicidality (under 25)	Black-box warning	Black-box warning

The pattern: SSRIs are more sedating, more weight-gaining, more sexually inhibiting, and more GI-disrupting. Bupropion is more activating, more weight-neutral or weight-losing, less sexually inhibiting, but more likely to cause insomnia, headache, and seizures (in susceptible patients).

Weight: the part patients ask about most

Weight effects are one of the biggest reasons patients switch between antidepressants. The data:

SSRIs as a class are associated with modest weight gain over months to years. The average weight gain in published meta-analyses is 1 to 3 pounds at 6 months and 5 to 10 pounds at 2 years. Paroxetine has the most weight gain among the SSRIs. Fluoxetine and sertraline are weight-neutral or lose weight in the first 3 months, then often gain through year 1.

Bupropion is weight-neutral or weight-losing. In trials, the average bupropion patient loses 2 to 4 pounds over 6 months. Patients who are obese or overweight at baseline tend to lose more (5 to 8 pounds at 6 months in some studies).

This weight difference is consistent enough that bupropion is often the antidepressant of choice for patients with depression and obesity. It's not powerful enough to qualify as a weight-loss medication on its own, which is why it's combined with naltrexone in Contrave specifically for weight management.

The mechanism for the weight difference isn't fully clear. Bupropion's dopamine effect may reduce reward-driven eating, and the norepinephrine effect may slightly increase resting energy expenditure. SSRIs may increase carbohydrate cravings via serotonin-mediated appetite pathways.

If you're choosing an antidepressant and weight is a concern, this is one of the cleanest decision points in psychiatry.

Sexual side effects: the part patients ask about second-most

Sexual dysfunction is the most common reason patients quietly stop taking SSRIs. The published rates depend heavily on how directly patients are asked. When asked indirectly, rates run 20 to 30%. When asked directly with structured questionnaires, rates run 50 to 70% for paroxetine and citalopram, 30 to 50% for sertraline and escitalopram, 25 to 40% for fluoxetine.

Bupropion's rates are dramatically lower, around 5 to 10% in head-to-head trials. Some patients report improved sexual function on bupropion compared to baseline, possibly via dopamine-mediated effects.

For patients on an SSRI with sexual dysfunction, three options exist:

1. Switch to bupropion (often effective if depression also responds)
2. Add bupropion alongside the SSRI (combination is sometimes used at lower doses of each)
3. Switch to another SSRI with a slightly lower rate (fluoxetine usually beats paroxetine)

Post-SSRI sexual dysfunction (PSSD) is a small but documented condition where sexual side effects persist after stopping an SSRI. It's rare but real. There's no equivalent reported for bupropion.

When bupropion is preferred, when an SSRI is preferred

Bupropion is often preferred when:

• The patient has obesity or wants to avoid weight gain
• Sexual side effects on a previous SSRI were a deal-breaker
• The patient has low energy or executive-function symptoms in their depression
• Smoking cessation is a concurrent goal
• ADHD is suspected as a comorbidity (off-label evidence)
• The patient has had GI side effects on previous SSRIs

An SSRI is often preferred when:

• The patient has prominent anxiety alongside depression (bupropion can worsen anxiety)
• The patient has insomnia or agitation as primary symptoms
• There's a history of seizures, eating disorders (bulimia or anorexia), or alcohol withdrawal (bupropion is contraindicated)
• The patient has obsessive-compulsive symptoms (SSRIs are first-line for OCD)
• Pregnancy or breastfeeding (sertraline is the most studied)
• Cost is a major issue (most SSRIs are inexpensive generics, as is bupropion, but tier coverage varies)

The clinical reality is that no single antidepressant works for everyone. STARD (the largest pragmatic depression trial in U.S. history) found roughly 33% remission rate with the first SSRI tried, climbing to 67% after up to 4 sequential treatment trials. Bupropion was used as a switch or augmentation drug in STARD level 2 and showed comparable efficacy to the SSRI alternatives.

Bupropion for smoking cessation and weight loss

Bupropion has FDA approvals beyond depression.

Smoking cessation (Zyban). Bupropion roughly doubles long-term smoking cessation rates compared to placebo, similar to nicotine replacement therapy. Combination of bupropion plus nicotine replacement is sometimes more effective than either alone. The mechanism is partly nicotinic receptor blockade plus dopamine modulation in reward pathways.

Weight management (Contrave, bupropion + naltrexone). Contrave combines bupropion 90 mg with naltrexone 8 mg in extended-release tablets. The combination produces about 5% body-weight loss at 1 year on average, which is meaningful but lower than what GLP-1 medications produce (15 to 20%). Contrave is sometimes used for patients who can't tolerate GLP-1 medications or who have specific medical contraindications.

For weight loss specifically, the comparison data:

Medication	Average weight loss at 1 year
Placebo (lifestyle only)	1-3%
Phentermine	5-7%
Contrave (bupropion + naltrexone)	5-9%
Orlistat	3-5%
Semaglutide 2.4 mg (Wegovy)	14-17%
Tirzepatide 15 mg (Zepbound)	18-21%

Contrave is a reasonable option for patients with depression and obesity who want both treated. It's not in the same league as GLP-1 medications for weight loss.

A note on FormBlends: we focus on compounded GLP-1 medications (semaglutide, tirzepatide) for weight management. We do not currently prescribe bupropion or Contrave. Patients who would benefit from bupropion-based therapy should talk with a primary care provider or psychiatrist. For patients whose primary goal is weight loss and who are appropriate candidates, GLP-1 medications generally produce 2 to 4x more weight loss than bupropion-based regimens.

The Contrave question

A common search pattern alongside "is bupropion an SSRI" is "is Contrave an SSRI." Contrave contains bupropion plus naltrexone. Neither component is an SSRI. Naltrexone is an opioid receptor antagonist, originally developed for alcohol use disorder and opioid dependence. The combination targets reward-driven eating via two mechanisms (dopamine modulation from bupropion, opioid receptor blockade from naltrexone).

Contrave is FDA-approved for chronic weight management in patients with BMI 30+ or BMI 27+ with weight-related comorbidities, in conjunction with diet and exercise.

Contrave's most relevant side effects are similar to bupropion alone (insomnia, headache, dry mouth) plus nausea and constipation from the naltrexone component. The seizure-risk warning from bupropion still applies.

Safety considerations and contraindications

Bupropion has stricter contraindications than most SSRIs. The clinically important ones:

Absolute contraindications:

• History of seizure disorder
• Current or prior diagnosis of bulimia or anorexia nervosa (higher seizure risk in these patients)
• Abrupt discontinuation of alcohol or sedatives (withdrawal lowers seizure threshold)
• Use of MAOIs within 14 days
• Known hypersensitivity to bupropion

Use with caution:

• Severe hepatic impairment (dose reduction needed)
• Severe renal impairment
• Recent traumatic brain injury or CNS tumor
• Concurrent medications that lower seizure threshold (some antipsychotics, tramadol, certain antibiotics)
• Hypertension (bupropion can modestly increase blood pressure)

The seizure risk is the headline contraindication. At standard therapeutic doses (300 mg/day immediate release or 300-450 mg/day extended release), seizure incidence is around 0.1% per year, comparable to or slightly higher than SSRIs. At higher doses (above 450 mg/day) the rate climbs sharply, which is why the maximum dose is capped.

For patients with any of the absolute contraindications, an SSRI is the safer choice.

FAQ

Is bupropion an SSRI?

No. Bupropion is an NDRI (norepinephrine-dopamine reuptake inhibitor). SSRIs increase serotonin; bupropion increases norepinephrine and dopamine.

Is Wellbutrin an SSRI?

No. Wellbutrin is a brand name for bupropion, which is an NDRI.

Is bupropion an antidepressant?

Yes. Bupropion is FDA-approved for major depressive disorder and seasonal affective disorder. It works through a different mechanism than SSRIs but is effective for both indications.

Why isn't bupropion classified as an SSRI?

Because it doesn't act on serotonin receptors or transporters in any meaningful way. The "SSRI" label specifically describes drugs that block the serotonin transporter (SERT). Bupropion blocks norepinephrine and dopamine transporters instead.

Can I take bupropion with an SSRI?

Sometimes, under provider supervision. Bupropion is sometimes added to an SSRI to address sexual side effects, low energy, or partial response. The combination is generally well tolerated. Don't combine without provider guidance because of the seizure-risk and serotonin-syndrome considerations.

Does bupropion cause weight gain like SSRIs?

No. Bupropion is weight-neutral or weight-losing in most patients. SSRIs as a class tend to cause modest weight gain over months to years.

Is bupropion stronger than an SSRI?

Not in a simple sense. Both classes have comparable response rates for major depression. Bupropion may work better for patients with prominent low-energy or executive-function symptoms. SSRIs may work better for patients with prominent anxiety symptoms.

Why is bupropion used for weight loss?

Bupropion modestly reduces appetite and may reduce reward-driven eating via dopamine modulation. Combined with naltrexone (in Contrave), it's FDA-approved for chronic weight management. Average weight loss is around 5 to 9% at 1 year, less than GLP-1 medications produce.

Can bupropion replace an SSRI?

For some patients, yes. Switching from an SSRI to bupropion is most successful for patients whose main complaints with the SSRI were sexual dysfunction, weight gain, or low energy. Patients with prominent anxiety often do worse on bupropion than on an SSRI.

Does bupropion work like Mounjaro or Ozempic?

No. Bupropion and GLP-1 medications work through completely different mechanisms. Bupropion modulates dopamine and norepinephrine in the brain. GLP-1 medications mimic gut hormones that slow gastric emptying and reduce appetite. The weight-loss magnitude is also very different (5 to 9% for Contrave at 1 year vs 15 to 20% for GLP-1 medications).

Is bupropion safer than an SSRI?

Neither class is universally safer. Bupropion has a higher seizure risk and stricter contraindications. SSRIs have higher rates of sexual dysfunction, weight gain, and discontinuation syndrome. The right answer depends on the patient.

Can FormBlends prescribe bupropion?

FormBlends focuses on compounded GLP-1 medications for weight management. We do not currently prescribe bupropion or Contrave. Patients who want bupropion-based therapy should consult a primary care provider or psychiatrist.

Author / review note

Reviewed by the FormBlends Medical Team. References cited above include the STARD trial publications (Rush et al., American Journal of Psychiatry*, 2006), the FDA prescribing information for Wellbutrin, Zyban, and Contrave, and the American Psychiatric Association Practice Guideline for the Treatment of Patients with Major Depressive Disorder, third edition.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wellbutrin, Zyban, Aplenzin, and Auvelity are registered trademarks of their respective owners. Contrave is a registered trademark of Currax Pharmaceuticals. Zoloft, Prozac, Lexapro, Celexa, Paxil, and Luvox are registered trademarks of their respective owners. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. Wegovy and Ozempic are registered trademarks of Novo Nordisk. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.